# LogicBio Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/logicbio-therapeutics

- Industry: Biotechnology
- Headquarters: Lexington, US
- Website: www.logicbio.com
- Total disclosed funding: $33M
- Latest round: Series B (Jun 19, 2017)
- Investors on record: 6

## About

LogicBio Therapeutics, Inc. is a biotechnology company specializing in gene therapies aimed at treating genetic diseases using its proprietary platform technology.Founded in 2014 and headquartered in Lexington, US, LogicBio Therapeutics, Inc. focuses on developing innovative genetic therapies. The company raised USD 70 mn in an IPO in October 2018 and later secured USD 42 mn in an equity offering in October 2020. Co-founders Adi Barzel and Mark Kay have a history of entrepreneurial experience, while Frederic Chereau serves as the current CEO.LogicBio Therapeutics, Inc. is dedicated to developing gene therapies that target genetic disorders, utilizing its proprietary genome editing technology. The company's primary focus is on advancing its product pipeline to address rare diseases, leveraging advanced scientific methods to improve treatment outcomes for patients.In the most recent year, LogicBio Therapeutics reported a revenue of USD 5.41 mn and an EBITDA of USD -38.36 mn, reflecting ongoing investments in research and development to further its therapeutic offerings.LogicBio Therapeutics, Inc. aims to expand its product pipeline by introducing new gene therapies designed for rare genetic disorders. The company is targeting expansion into new markets, particularly in Europe and Asia, by 2023. Recent funding from the Trade Sale, amounting to USD 68 mn, will be utilized to accelerate R&D efforts, enhance clinical trials, and support marketing strategies to facilitate entry into these new regions.

## Funding rounds

- Series B, Jun 19, 2017, $29M — OrbiMed Advisors, Andera Partners, Pontifax Venture Capital, Edmond de Rothschild Group, Arix Bioscience, SBI JI Innovation Advisory
- Series A, Jan 13, 2016, $4M — OrbiMed Advisors

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series B
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series B
- Edmond de Rothschild Group — Series B
- Arix Bioscience (https://capitalatlas.ai/funds/arix-bioscience) — Series B
- SBI JI Innovation Advisory (https://capitalatlas.ai/funds/sbi-ji-innovation-advisory) — Series B